{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:15:52Z","timestamp":1788218152279,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.radonc.2026.111571","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:16:47Z","timestamp":1778451407000},"page":"111571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy induced nausea and vomiting (RINV): CTRI\/2022\/01\/039723"],"prefix":"10.1016","volume":"221","author":[{"given":"Meenu","family":"Vijayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Narmadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haridas","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Namratha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.S.","family":"Sheejamol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debnarayan","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111571_b0005","doi-asserted-by":"crossref","unstructured":"Feyer P, Jahn F, Jordan K. Prophylatic management of radiation -induced nausea and vomiting. Biomed Res Int, 2015.","DOI":"10.1155\/2015\/893013"},{"key":"10.1016\/j.radonc.2026.111571_b0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2007.0008","article-title":"Radiation-induced nausea and vomiting","volume":"5","author":"Urba","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2026.111571_b0015","first-page":"1493","article-title":"A prospective study of gastrointestinal radiation therapy \u2013induced nausea and vomiting","volume":"22","author":"Poon","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.radonc.2026.111571_b0020","first-page":"171","article-title":"Can olanzapine preserve life quality in cancer patients undergoing abdominal\/pelvic radiation therapy?","volume":"1","author":"Vijayan","year":"2023","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.radonc.2026.111571_b0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111571_b0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111571_b0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111571_b0040","doi-asserted-by":"crossref","unstructured":"Gao J, Zhao J, Jiang C, Chen F, et al. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Supportive care in cancer.2022 Jul;30(7):6225-6232.","DOI":"10.1007\/s00520-022-07067-6"},{"key":"10.1016\/j.radonc.2026.111571_b0045","unstructured":"https:\/\/dcf.psychiatry.ufl.edu\/files\/2011\/05\/HAMILTON-ANXIETY.pdf."},{"key":"10.1016\/j.radonc.2026.111571_b0050","unstructured":"https:\/\/dcf.psychiatry.ufl.edu\/files\/2011\/05\/HAMILTON-DEPRESSION.pdf."},{"key":"10.1016\/j.radonc.2026.111571_b0055","article-title":"A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)","volume":"15","author":"Zhao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.radonc.2026.111571_b0060","article-title":"Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies","volume":"23","author":"Adel","year":"2017","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.radonc.2026.111571_b0065","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J Support Oncol"},{"key":"10.1016\/j.radonc.2026.111571_b0070","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fnins.2017.00741","article-title":"The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment","volume":"22","author":"Raben","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.radonc.2026.111571_b0075","doi-asserted-by":"crossref","unstructured":"Sutherland A, Naessens K, Plugge E,et al: Olanzapine for the prevention and treatment of cancer\u2010related nausea and vomiting in adults Cochrane Database Syst Rev 9,2018.","DOI":"10.1002\/14651858.CD012555.pub2"},{"key":"10.1016\/j.radonc.2026.111571_b0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11864-020-00804-1","article-title":"The benefits of olanzapine in palliating symptoms","volume":"22","author":"Davis","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.radonc.2026.111571_b0085","article-title":"Atypical antipsychotics: sleep, sedation, and efficacy","volume":"6","author":"Miller","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.radonc.2026.111571_b0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.radonc.2026.111571_b0095","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3389\/fphar.2020.00739","article-title":"Increased appetite plays a key role in olanzapine-induced weight gain in first-episode schizophrenia patients","volume":"11","author":"Huang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.radonc.2026.111571_b0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0885-3924(02)00378-0","article-title":"Olanzapine in the management of cancer pain","volume":"23","author":"Khojainova","year":"2002","journal-title":"J Pain Symptom Manage"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402600410X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402600410X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:51:15Z","timestamp":1783147875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402600410X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"alternative-id":["S016781402600410X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111571","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy induced nausea and vomiting (RINV): CTRI\/2022\/01\/039723","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111571"}}